You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Attention Score in Context
| Title |
BNT162b2 mRNA COVID-19ワクチン接種後に発症した後天性血友病A
|
|---|---|
| Published in |
[Rinshō ketsueki] The Japanese journal of clinical hematology, February 2023
|
| DOI | 10.11406/rinketsu.64.35 |
| Pubmed ID | |
| Authors |
Ayami Senda, Hideaki Saito, Shinsuke Kusakabe, Koki Yoshida, Kumi Shibata, Shuhei Kida, Jun Toda, Akihisa Hino, Tomoaki Ueda, Jiro Fujita, Kentaro Fukushima, Takafumi Yokota, Hirokazu Kashiwagi, Naoki Hosen |
| Abstract |
Acquired hemophilia A (AHA) is a rare disease characteized by bleeding symptoms caused by decreased factor VIII activity due to the appearance of inhibitors to factor VIII triggered by malignancy or collagen disease. An 86-year-old woman developed purpura on her extremities after the first dose of the BNT162b2 mRNA COVID-19 vaccine. This symptom subsided after a few days. After the second dose of the BNT162b2 mRNA COVID-19 vaccine, purpura appeared again, and the patient was referred to our hospital Her APTT was remarkably prolonged to 110 seconds, and a cross-mixing test revealed an inhibitor pattern. Since FVIII activity was <1% and FVIII inhibitor was 51.6 BU, she was diagnosed with AHA. Prednisolone therapy was started, and coagulative complete remission was achieved. Because acquired hemophilia can develop after mRNA COVID-19 vaccination, as in this case, it is critical to monitor the appearance of bleeding symptom. |
X Demographics
The data shown below were collected from the profiles of 41 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 3 | 7% |
| United States | 3 | 7% |
| Spain | 2 | 5% |
| Sweden | 1 | 2% |
| Lesotho | 1 | 2% |
| Unknown | 31 | 76% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 40 | 98% |
| Practitioners (doctors, other healthcare professionals) | 1 | 2% |
Attention Score in Context
This research output has an Altmetric Attention Score of 26. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2023.
All research outputs
#1,502,839
of 25,852,155 outputs
Outputs from [Rinshō ketsueki] The Japanese journal of clinical hematology
#4
of 727 outputs
Outputs of similar age
#32,752
of 488,980 outputs
Outputs of similar age from [Rinshō ketsueki] The Japanese journal of clinical hematology
#2
of 43 outputs
Altmetric has tracked 25,852,155 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 727 research outputs from this source. They receive a mean Attention Score of 1.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 488,980 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 43 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.